Neuromyelitis optica is an autoimmune disorder, in which white blood cells and antibodies attack optic nerve as well as spinal cord. Furthermore, damage of the optics nerves results in pain and loss of vision, while damage of spinal cord results in paralysis of legs or arms, loss of sensation in legs and arms, and problem in the function of bladder & bowel.

Moreover, there is no cure for neuromyelitis optica disorder, but there are therapies to treat acute attack of relapses, and to reduce symptoms. Neuromyelitis optica attacks and Neuromyelitis optica relapses are often treated with plasma exchange and corticosteroids. Moreover, initial symptoms of neuromyelitis optica such as vision loss and paralysis can be improve with high doses of intravenous corticosteroids. On the other hand, plasma exchange can be used as alternative, if the patient do not respond to intravenous corticosteroids. For long term suppression of disease, immunosuppressive agents such as azathioprine, mycophenolate mofetil, and rituximab are used to prevent the attack. Sometimes, azathioprine and mycophenolate mofetil are used with the low doses of corticosteroid to prevent the attack.

Global Neuromyelitis Optica Therapy Market Drivers

The global neuromyelitis optica therapy market is expected to witness significant growth over the forecast period, owing to increasing collaborations to launch new drugs for the treatment of neuromyelitis optica spectrum disorder. For instance, in May 2019, in China, Viela Bio, Inc. entered into strategic collaboration with Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”) to develop as well as commercialize inebilizumab drug for the treatment of autoimmune disorder such as neuromyelitis optica spectrum disorder. From the same source, in May 2019, Viela Bio had presented positive result from the pivotal study of inebilizumab in patient. Moreover, currently inebilizumab drug is not approved by the U.S Food and Drug Administartion (FDA) for sale in China and U.S.

Furthermore, rising incidence of neuromyelitis optica disorder among people is expected to propel global neuromyelitis optica therapy market growth. For instance, according to the U.S National Library of Medicine (NHS) 2019 report, prevalence of neuromyelitis optica spectrum disorders (NMOSD) is commonly observed in nations with a predominately non-Caucasian population and estimated to be high as 10 per 100,000 individuals.

Global Neuromyelitis Optica Therapy Market Restraints

However, high cost of drug such as eculizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD) yet remains one of the major restraints for global neuromyelitis Optica therapy market growth. For instance, cost of eculizumab is US$ 500,000 per patient per year, which is one of the most expensive therapies in the world for the treatment of neuromyelitis optica spectrum disorder (NMOSD).

Moreover, side effects associated with the eculizumab such as upper respiratory tract infection, back pain, anemia, nasal congestion, urinary tract infection for the treatment of neuromyelitis optica spectrum disorder (NMOSD) is another factor that is expected to hamper the global neuromyelitis optica therapy market growth.

Global Neuromyelitis Optica Therapy Market Regional Analysis

Among regions, North America is expected to account for highest market share in the global neuromyelitis optica therapy market, owing to factors such as increasing approval of drugs for the treatment of neuromyelitis optica spectrum disorder (NMOSD) by company. For instance, in January 2019, Alexion Pharmaceuticals, Inc. received approval by the U.S Food and Drug Administartion (FDA) for eculizumab (Soliris) drug for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients.  Furthermore, from the same source, eculizumab (soliris) has reduced the need of corticosteroid and plasma exchange to prevent acute attack in patients, who are suffering from neuromyelitis optica spectrum disorder (NMOSD).

Asia Pacific is expected to exhibit highest CAGR in the global neuromyelitis optica therapy market in the forecast period due to increasing approval of drug for the treatment of neuromyelitis optica spectrum disorder (NMOSD) by company. For instance, in November 2019, Alexion Pharmaceuticals, Inc. received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its Soliris (eculizumab) drug for the treatment of neuromyelitis optica spectrum disorder (NMOSD) to prevent relapse in patient.  

Furthermore, increasing number of clinical trials of drug for the treatment of neuromyelitis optica spectrum disorder (NMOSD) by company is another factor that is expected to drive the global neuromyelitis optica therapy market growth. For instance, in September 2019, Chugai Pharmaceutical Co., Ltd.  announced positive results of its phase 3 clinical study of satralizumab drug, for the treatment of neuromyelitis optica spectrum disorder (NMOSD). From the same source, in 2019, Satralizumab had shown safety profile during the clinical trial and is first investigational drug that had demonstrated benefits both as a monotherapy and add-on therapy to baseline treatment in two different clinical trials. Furthermore, from the same source, in 2019, Chugai Pharmaceutical Co., Ltd also announced that they are going to collaborate with F. Hoffmann-La Roche AG Company. The main objective of this collaboration with Hoffmann-La Roche AG company is to file global regulatory application and bring Satralizumab as a potential new treatment to patients as soon as possible.

Furthermore, in October 2019, European Medicines Agency (EMA) and U.S. FDA accepted the marketing authorization of Satralizumab drug for the treatment of neuromyelitis optica spectrum disorder in adults and adolescent patients, which was announced by Chugai Pharmaceutical Co., Ltd.

Global Neuromyelitis Optica Therapy Market Key Players

Key players operating in the global neuromyelitis optica therapy market include Alexion Pharmaceuticals Inc., Chugai Pharmaceutical Co., Ltd., Viela Bio, Inc, Hansoh Pharmaceutical Group Company Limited, AstraZeneca plc, F. Hoffmann-La Roche AG, Zydus Pharmaceuticals (USA) Inc., Alkem Laboratories, Hikma Pharmaceuticals USA Inc., and Sandoz Inc.

Market Taxonomy:

On the basis of drug class, the global neuromyelitis optica therapy market is segmented into:

  • Corticosteroids
  • Immunosuppressive Agents 
    • Azathioprine
    • Mycophenolate Mofetil
    • Rituximab
    • Eculizumab
  • Others

On the basis of distribution channel, the global neuromyelitis optica therapy market is segmented into:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

On the basis of region, the global neuromyelitis optica therapy s market is segmented into:

  • North America
  • Latin America
  • Europe
  • Middle East
  • Asia Pacific
  • Africa
N/A
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner